Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs

Bennet, Sean; Böhn, Lena; Störsrud, Stine; Liljebo, Therese; Collin, Lena; Lindfors, Perjohan; Törnblom, Hans; Öhman, Lena; Simrén, Magnus

doi:10.1136/gutjnl-2016-313128

Cited by 193 publications

(199 citation statements)

References 36 publications

Supporting

Mentioning

179

Contrasting

Unclassified

Order By: Relevance

“…71 However, long term use of such an intervention can decrease microbial short chain fatty acid production which in turn may have negative implications for human health. A recent study identified microbiome markers which predict a positive response to FODMAP 72 with the potential to allow optimization of therapy and minimizing undesirable adverse effects in individuals less likely to respond. An important aspect of the gut microbiome is its role in determining host responses to dietary components given that the microbiome plays an important role in metabolism of dietary nutrients.…”

Section: Targeting the Microbiome To Improve Healthmentioning

confidence: 99%

Microbiome at the Frontier of Personalized Medicine

Kashyap

Chia

Nelson

et al. 2017

Mayo Clinic Proceedings

170

View full text Add to dashboard Cite

The genomic revolution promises to transform our approach to treating patients by individualizing treatments, reducing adverse events and decreasing healthcare costs. The early advances using this have been realized primarily by optimizing preventive and therapeutic approaches in cancer using human genome sequencing. The ability to characterize the microbiome, which includes all the microbes that reside within and upon us and all their genetic elements, using next-generation sequencing, allows us to now incorporate this important contributor to human disease in developing new preventive and therapeutic strategies. In this review we highlight the importance of the microbiome in all aspects of human disease including pathogenesis, phenotype, prognosis and response to treatment as well their role as diagnostic and therapeutic biomarkers. We provide a role for next-generation sequencing in both precise microbial identification for infectious diseases as well as characterization of microbial communities and their function. Taken together, the microbiome is emerging as an integral part of precision medicine approach as it not only contributes to inter-individual variability in all aspects of a disease but also represents a potentially modifiable factor that is amenable to targeting by therapeutics.

show abstract

Section: Targeting the Microbiome To Improve Healthmentioning

confidence: 99%

Microbiome at the Frontier of Personalized Medicine

Kashyap

Chia

Nelson

et al. 2017

Mayo Clinic Proceedings

170

View full text Add to dashboard Cite

show abstract

“…I ein ny studie er samanhengen mellom fekal bakterieprofil og respons på diettbehandling ved irritabel tarm-syndrom undersøkt (1). Studien byggjer på sekundaeranalysar av 61 pasientar frå ein intervensjonsstudie.…”

Section: Illustrasjonsfoto: Chrischrisw/istockunclassified

Kan tarmfloraen føreseie effekt av behandling?

Lillestøl¹

2018

Tidsskriftet

View full text Add to dashboard Cite

Respons på diettbehandling ved irritabel tarm-syndrom kan vere knytt til pasientens tarmbakterieprofil. Illustrasjonsfoto: ChrisChrisW/iStockBehandling av irritabel tarm-syndrom (IBS) er utfordrande. Diett lettar plagene for somme, men det gjeld langt frå alle, og det er førebels vanskeleg å seie på førehand kven som responderer på slik intervensjon.I ein ny studie er samanhengen mellom fekal bakterieprofil og respons på diettbehandling ved irritabel tarm-syndrom undersøkt (1). Studien byggjer på sekundaeranalysar av 61 pasientar frå ein intervensjonsstudie. Pasientane vart randomisert til å følgje anten ein såkalla tradisjonell IBS-diett, eller ein diett med lågt inntak av FODMAP (fermenterbare oligosakkarid, disakkarid, monosakkarid og polyolar). Det vart samla avføringsprøver til analyse av bakterieprofilar. I gruppa som fekk låg-FODMAP-diett, var det fleire skilnader i fekal bakterieprofil mellom dei som responderte på behandling og dei som ikkje gjorde det,

show abstract

“…Patients with IBS following a low FODMAP diet had significant decreases from baseline in the quantity of fecal bacteria (i.e. Mycoplasma hominis, Bifidobacterium, Actinobacteria) after 4 weeks [51]. However, the implications of a long-term low FODMAP diet on the gut microbiota in IBS are currently unknown [50].…”

Section: Low Fodmap Dietmentioning

confidence: 99%

Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome

Harris

Baffy

2017

Postgraduate Medicine

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS), which is characterized by recurrent abdominal pain and disordered bowel habits, is one of the most common functional bowel disorders. IBS is a substantial burden on both patient health-related quality of life and healthcare costs. Several pathophysiologic mechanisms have been postulated for the occurrence of IBS, including altered gastrointestinal motility, visceral hypersensitivity, changes in gut permeability, immune activation, gut-brain dysregulation, central nervous system dysfunction, and changes in the gut microbiota. Of note, both qualitative and quantitative differences have been observed in the gut microbiota of a population with IBS versus a healthy population. Because of the substantial interest in the gut microbiota and its role as a therapeutic target in IBS, this article provides an overview of specific interventions with the potential to modulate the gut microbiota in IBS, including elimination diets, prebiotics, probiotics, synbiotics, and nonsystemic antibiotics. Although probiotics and synbiotics are generally well tolerated, differences in the composition and concentration of different bacterial species and inclusion or exclusion of prebiotic components varies widely across studies and has prevented strong recommendations on their use in IBS. For nonsystemic antibiotics, rifaximin is indicated in the United States for the treatment of IBS with diarrhea in adults and has been shown to be efficacious and well tolerated in well-designed clinical trials. Overall, more consistent evidence is needed regarding the efficacy and safety of elimination diets, prebiotics, probiotics, and synbiotics for the treatment of patients with IBS. Furthermore, additional well-designed studies are needed that examine alterations in the gut microbiota that occur with these interventions and their potential associations with clinical symptoms of IBS. ARTICLE HISTORY

show abstract

Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs

Abstract: NCT02107625.

Cited by 193 publications

References 36 publications

Microbiome at the Frontier of Personalized Medicine

Microbiome at the Frontier of Personalized Medicine

Kan tarmfloraen føreseie effekt av behandling?

Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome

Contact Info

Product

Resources

About